Business Wire

Cessna Citation Longitude and Citation Ascend to Debut at AERO Friedrichshafen Alongside Legendary Lineup of Cessna, Beechcraft and Pipistrel Aircraft

9.4.2026 13:00:00 CEST | Business Wire | Press Release

Share

The Cessna Citation Longitude and the Cessna Citation Ascend, designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, are expected to make their show debut alongside a legendary lineup of Cessna, Beechcraft and Pipistrel aircraft at AERO Friedrichshafen, April 22–25 in Friedrichshafen, Germany. This is also the European show debut for the Citation Ascend.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260409641450/en/

Cessna Citation Longitude and Citation Ascend to debut at AERO Friedrichshafen alongside legendary lineup of Cessna, Beechcraft and Pipistrel aircraft (Photo Credit: Textron Aviation).

Textron Aviation holds a strong position in business and general aviation in Germany and the surrounding area, with more than 1,700 turbine aircraft in region. More than 850 Cessna Citation business jets, 450 Beechcraft King Air turboprops and 175 Cessna Caravan turboprops are based in Europe.

“We designed the Citation Ascend by listening to customers, then elevating an iconic platform to deliver more capability, comfort and confidence for every mission,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “At AERO Friedrichshafen, we’re proud to bring the Ascend to Europe and show how its modern avionics, refined cabin and proven performance are purpose-built for operators here and around the world.”

In addition to the Citation Longitude and Citation Ascend, the following aircraft are expected to be on display at the Textron Aviation static display SD-11, at Messe Friedrichshafen:

In the Textron Aviation booth A2-130, attendees can engage with representatives from the company’s aftermarket parts and support teams and McCauley Propeller Systems, as well as view the following aircraft:

Textron Aviation delivers comprehensive global Aftermarket service and support for Cessna and Beechcraft customers, providing complete life‑cycle support wherever aircraft operate. In Europe, customers are supported by a robust regional footprint that includes five company‑owned service centers, a network of Authorized Service Facilities (ASFs) and mobile service support teams, ensuring responsive, expert care close to home. European operators also benefit from the company’s European Parts Distribution Center (EUDC), which provides fast shipping, reliable access to genuine parts and dedicated in‑region customer support. Backed by 24/7 Aircraft‑On‑Ground (AOG) assistance, Textron Aviation helps minimize downtime and keep customers flying — supporting aircraft such as the new Cessna Citation Ascend from entry into service and throughout its life cycle.

About the Cessna Citation Ascend
Textron Aviation designed the Citation Ascend based on customer feedback for ultimate performance and comfort. With sleek and modern features, customers can enjoy many of the luxuries found in the best-selling Cessna Citation Latitude and Cessna Citation Longitude, including a flat floor to provide generous legroom and flexibility for passengers. The aircraft offers Pratt & Whitney Canada PW545D engines designed to deliver fuel efficiency and increased thrust, as well as Garmin G5000 avionics that feature the latest software and hardware, including autothrottle technology. The Ascend also features a Honeywell RE100 [XL] Auxiliary Power Unit (APU) approved for unattended operations.

With 19 standard USB charging ports and three universal outlets throughout the aircraft, all crew and passengers have access to at least one charging port in the Citation Ascend. The aircraft can be configured for up to 12 passengers.

Learn more about the Citation Ascend at cessna.com/ascend.

About Textron Aviation Inc.
We have been inspiring the journey of flight for nearly 100 years. Textron Aviation Inc., a Textron Inc. company, has empowered our collective talent across the Beechcraft, Cessna, Hawker and Pipistrel brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, light and high-performance pistons, to special mission, military trainer and defense aircraft, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable, productive and flexible flight. For more information, visit www.txtav.com.

About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, and Textron Systems. For more information, visit: www.textron.com.

Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to: changes in aircraft delivery schedules or cancellations or deferrals of orders; our ability to keep pace with our competitors in the introduction of new products and upgrades with features and technologies desired by our customers; changes in government regulations or policies on the export and import of our products; volatility in the global economy or changes in worldwide political conditions that adversely impact demand for our products; and risks related to our international business, including establishing and maintaining facilities in locations around the world and relying on joint venture partners, subcontractors, suppliers, representatives, consultants and other business partners in connection with international business, including in emerging market countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409641450/en/

Contacts

Media Contact
Kate Flavin
+1.316.252.7780
kflavin@txtav.com
txtav.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.txtav.com&e
sheet=54486260&newsitemid=20260409641450&lan=en-US&anchor=txtav.com&index=18&md5
=9d551a37970a23f12e9edce79a2bbe99

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye